MARKET

NERV

NERV

Minerva Neurosci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3721
-0.0190
-4.86%
Closed 16:00 05/20 EDT
OPEN
0.3891
PREV CLOSE
0.3911
HIGH
0.3891
LOW
0.3500
VOLUME
52.31K
TURNOVER
--
52 WEEK HIGH
3.535
52 WEEK LOW
0.3305
MARKET CAP
15.90M
P/E (TTM)
-0.3125
1D
5D
1M
3M
1Y
5Y
BRIEF-Minerva Neurosciences QTRLY Net Loss Per Share $0.23
reuters.com · 05/04 14:12
Recap: Minerva Neurosciences Q1 Earnings
  Minerva Neurosciences (NASDAQ:NERV) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 13:22
Minerva Neurosciences GAAP EPS of -$0.23 misses by $0.05
Minerva Neurosciences press release (NASDAQ:NERV): Q1 GAAP EPS of -$0.23 misses by $0.05. Cash, cash equivalents, and restricted cash as of March 31, 2022 and December 31, 2021 were approximately
Seekingalpha · 05/04 12:44
Minerva Outlines Next Steps For US Application For Schizophrenia Candidate
Minerva Neurosciences Inc (NASDAQ: NERV) received the 
Benzinga · 04/07 16:49
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.
Zacks · 04/07 13:57
Minerva gets FDA meeting minutes on its treatment for negative symptoms in schizophrenia
Biopharmaceutical company Minerva Neurosciences (NASDAQ:NERV) has received the official meeting minutes from the March type C meeting with the U.S. FDA regarding the development of the company's compound roluperidone to treat
Seekingalpha · 04/07 13:49
Minerva Neurosciences Reports Received Minutes From Recent Type C Meeting With FDA: FDA Division Agreed Studies For Its Schizophrenia Treatment Showed Promising Signals
Company to Host Webcast Wednesday, April 13, 2022 at 11am ET WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company developing therapies
Benzinga · 04/07 12:33
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Company to Host Webcast Wednesday, April 13, 2022 at 11am ETWALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system (CNS)...
GlobeNewswire · 04/07 12:30
More
No Data
Learn about the latest financial forecast of NERV. Analyze the recent business situations of Minerva Neurosci through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
50.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NERV stock price target is 6.67 with a high estimate of 9.00 and a low estimate of 5.00.
High9.00
Average6.67
Low5.00
Current 0.3721
EPS
Actual
Estimate
-0.40-0.30-0.20-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 92
Institutional Holdings: 32.30M
% Owned: 75.61%
Shares Outstanding: 42.72M
TypeInstitutionsShares
Increased
2
189.75K
New
5
54.22K
Decreased
14
875.13K
Sold Out
6
424.25K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Remy Luthringer
President
Geoffrey Race
Chief Financial Officer/Senior Vice President/Secretary
Frederick Ahlholm
Chief Operating Officer/Senior Vice President
Joseph Reilly
Senior Vice President
Ramana Kuchibhatla
Other
Michael Davidson
Lead Director/Independent Director
William Doyle
Independent Director
Hans Hasler
Independent Director
Jeryl Hilleman
Independent Director
David Kupfer
Independent Director
Fouzia Laghrissi-Thode
Independent Director
Jan van Heek
No Data
No Data
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101), MIN-301, and seltorexant. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders. The Company is developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD).

Webull offers kinds of Minerva Neurosciences Inc stock information, including NASDAQ:NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NERV stock methods without spending real money on the virtual paper trading platform.